Matthew Biegler
Stock Analyst at Oppenheimer
(3.44)
# 932
Out of 5,072 analysts
85
Total ratings
38.16%
Success rate
8.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OLMA Olema Pharmaceuticals | Maintains: Outperform | $22 → $45 | $28.12 | +60.03% | 8 | Nov 18, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $12 → $15 | $11.82 | +26.90% | 6 | Nov 14, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Maintains: Outperform | $23 → $22 | $12.18 | +80.62% | 2 | Nov 13, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $30 → $28 | $17.20 | +62.79% | 3 | Oct 10, 2025 | |
| ACRV Acrivon Therapeutics | Maintains: Outperform | $9 → $8 | $2.36 | +238.98% | 4 | Aug 14, 2025 | |
| CTMX CytomX Therapeutics | Initiates: Outperform | $7 | $4.22 | +65.88% | 1 | Jul 31, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $10 → $9 | $1.42 | +533.80% | 2 | May 14, 2025 | |
| VOR Vor Biopharma | Reiterates: Outperform | $160 | $7.95 | +1,912.58% | 7 | Mar 21, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $40 → $45 | $12.42 | +262.32% | 5 | Feb 12, 2025 | |
| GILD Gilead Sciences | Reiterates: Outperform | $105 → $115 | $127.51 | -9.81% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $53 | $35.88 | +47.71% | 5 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $33 | $22.03 | +49.80% | 6 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $1.44 | +1,288.89% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $8.03 | - | 6 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $7.60 | - | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $11.32 | +23.67% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $9.15 | - | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.10 | - | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $9.41 | - | 2 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.83 | - | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.98 | - | 2 | Dec 22, 2022 |
Olema Pharmaceuticals
Nov 18, 2025
Maintains: Outperform
Price Target: $22 → $45
Current: $28.12
Upside: +60.03%
ORIC Pharmaceuticals
Nov 14, 2025
Maintains: Outperform
Price Target: $12 → $15
Current: $11.82
Upside: +26.90%
BridgeBio Oncology Therapeutics
Nov 13, 2025
Maintains: Outperform
Price Target: $23 → $22
Current: $12.18
Upside: +80.62%
Nurix Therapeutics
Oct 10, 2025
Maintains: Outperform
Price Target: $30 → $28
Current: $17.20
Upside: +62.79%
Acrivon Therapeutics
Aug 14, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $2.36
Upside: +238.98%
CytomX Therapeutics
Jul 31, 2025
Initiates: Outperform
Price Target: $7
Current: $4.22
Upside: +65.88%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $10 → $9
Current: $1.42
Upside: +533.80%
Vor Biopharma
Mar 21, 2025
Reiterates: Outperform
Price Target: $160
Current: $7.95
Upside: +1,912.58%
Arvinas
Feb 12, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $12.42
Upside: +262.32%
Gilead Sciences
Dec 10, 2024
Reiterates: Outperform
Price Target: $105 → $115
Current: $127.51
Upside: -9.81%
Oct 29, 2024
Reiterates: Outperform
Price Target: $53
Current: $35.88
Upside: +47.71%
Sep 19, 2024
Maintains: Outperform
Price Target: $25 → $33
Current: $22.03
Upside: +49.80%
Sep 16, 2024
Reiterates: Outperform
Price Target: $20
Current: $1.44
Upside: +1,288.89%
Sep 10, 2024
Downgrades: Perform
Price Target: n/a
Current: $8.03
Upside: -
Jul 2, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $7.60
Upside: -
May 14, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $11.32
Upside: +23.67%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $9.15
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.10
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $9.41
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.83
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.98
Upside: -